Subsequent treatments.
ST subsequent treatment, VEGFi vascular endothelial growth factor inhibitor, PARPi poly ADP-ribose polymerase inhibitors, PLD pegylated liposomial doxorubicin.Two-hundred and thirty-one patients (76.0%) in the carboplatin/PLD group and 240 (78.2%) patients in the trabectedin/PLD died. Median overall survival was 21.4 months (95% CI 19.0–25.4) with carboplatin/PLD and 21.9 months (95% CI 18.1–24.1) with trabectedin/PLD (HR 1.13 [95% CI 0.94–1.35]; 